Table 2.
Study Visit | Age, y | Height, cm (SDS) | HV, cm/y (SDS) | BMI, kg/m2 (SDS) | Bone Age, y | Test. Vol., mL | Total IGF-1, ng/mL | Free IGF-1, µg/L | PAPP-A2, µg/L | IGFBP-3, ng/mL | ALS, mg/L | GH, ng/mL |
---|---|---|---|---|---|---|---|---|---|---|---|---|
P3a baseline | 10.4 | 122 (−2.9) | 3 (−2.8) | 14 (−1.5) | 9 | 3 | 546.8 | 0.79 | 0.11 | >10,000 | 18 | 0.2 |
3 mob | 10.7 | 123.1 (−2.8) | — | 14.7 (−1.4) | — | 3 | 524.0 | 0.35 | 0.133 | >10,000 | 22 | 0.8 |
6 mo | 11 | 125.7 (−2.6) | — | 15.7 (−0.7) | — | 3 | 688.9 | 1.05 | 0.176 | 6141 | 14 | 0.1 |
9 mo | 11.2 | 127 (−2.5) | — | 16 (−0.6) | — | 3 | 739.2 | 1.67 | 0.157 | 6492 | 11 | 0.1 |
12 mo | 11.4 | 128.2 (−2.5) | 6.2 (+1.2) | 16.4 (−0.5) | 10 | 3 | 709.1 | 1.17 | 0.19 | 6362 | 14 | 0.1 |
P2 baseline | 14.5 | 142.4 (−2.9) | 4.3 (−1.6) | 27 (+1.7) | 13.5 | 6 | 573.2 | 5.59 | 0.064 | 8997 | 23 | 0.1 |
3 mo | 14.8 | 143.5 (−2.9) | — | 27 (+1.7) | — | — | 656.3 | 5.93 | 0.088 | >10,000 | 24 | 0.1 |
12 mo | 15.5 | 147.2 (−3.0) | 4.8 (+1.5) | 27 (+1.7) | 14.5 | 12 | 756.2 | 6.07 | 0.135 | 8983 | 17 | 0.1 |
Reference values for P3 (10-year-old boy): Total IGF-1, 104–430 ng/mL; IGFBP-3, 2343–5879 ng/mL; ALS, 5.6–16 mg/L.
Reference values for P2 (14-year-old boy): Total IGF-1, 150–554 ng/mL; IGFBP-3, 2599–6294 ng/mL; ALS, 5.6–16 mg/L.
Reference values for PAPP-A2: Tanner I, 0.16–2.69 µg/L; Tanner V, 0.23–0.80 µg/L.
Reference values for free IGF-1: Tanner I, 1.58–3.15 µg/L; Tanner V, 4.89–9.37 µg/L.
Abbreviations: BMI, body mass index; HV, height velocity; Test. Vol., testicular volume.
P3 was treated with rhIGF-1.
P3 was not receiving rhIGF-1 treatment at the time of the study visit.